Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Bioavailability of Clonidine MBT vs Catapres in Healthy Volunteers
NCT02548806Phase 1Completed
- Sponsor
- Valerio Therapeutics
- Start
- Sep 2015
- Primary completion
- Dec 2015
- Modality
- Small Molecules, Device-based Delivery
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of Clonidine Lauriad in oral mucositis (OM) (3 arms), sponsored by Valerio Therapeutics. Primary endpoints: Pharmacokinetic dose proportionality of Clonidine MBT 50 μg and 100 μg at 3 Months and Comparative bioavailability of clonidine from Clonidine MBT vs Catapres at 3 Months. Started Sep 2015; status: completed.
02
Drugs
Clonidine Lauriad
03
Conditions
oral mucositis (OM)
Beyond the preview
Go deeper on NCT02548806.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02548806.